The final, formatted version of the article will be published soon.
CASE REPORT article
Front. Oncol.
Sec. Thoracic Oncology
Volume 14 - 2024 |
doi: 10.3389/fonc.2024.1467344
Thoracic schwannoma as a diagnostic pitfall in both 18 F-Choline PET/CT and 18 F-FDG PET/CT Incidentaloma of a schwannoma
Provisionally accepted- 1 Departement of Medical Oncology , Morlaix Hospital, Morlaix, France, Morlaix, France
- 2 Département de Radiothérapie, Centre Hospitalier Regional Universitaire (CHU) de Brest, Brest, Brittany, France
- 3 Ouest Pathologie (OP), Quimper, France
- 4 Department of Radiology, University Hospital of Brest, France, Brest, France
- 5 Department of Nuclear Medicine, University Hospital of Brest, France, Brest, Brittany, France
- 6 UMR Inserm 1304 GETBO, IFR 148, University of Western Brittany, Brest, France, Brest, Brittany, France
We report increased 18 F-FDG uptake in the right posterior mediastinal region in a 70-year-old woman following the discovery of a mass in the aftermath of a bronchitis episode. We also report increased 18 F-Choline uptake in the right posterior mediastinal region in a 66-year-old man with newly discovered prostate cancer, which may indicate the presence of mediastinal metastases. Both patients had a thoracic MRI showing an intense gadolinium enhancement in the same region, consistent with thoracic schwannomas, which were subsequently proven histologically. This case highlights that schwannoma is a diagnostic pitfall in both 18 F-FDG and 18 F-Choline PET/CT.
Keywords: prostate cancer, thoracic schwannoma, 18 F-choline PET/CT, MRI, FDG-PET/CT
Received: 19 Jul 2024; Accepted: 09 Sep 2024.
Copyright: © 2024 AMRANE, Le Meur, PIERRE, Niel, Renault, Peillon, Tissot and ABGRAL. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Karim AMRANE, Departement of Medical Oncology , Morlaix Hospital, Morlaix, France, Morlaix, France
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.